non-small cell lung cancer

ImmunityBio Reports Encouraging Evidence That ANKTIVA Enhances Immune Recovery in NSCLC When Paired With Checkpoint Inhibitors

Post author:Austin Newman
Post published:January 22, 2026
Post category:non-small cell lung cancer

As reported on Business Wire, ImmunityBio has released new clinical findings suggesting that its interleukin‑15 superagonist, ANKTIVA® (nogapendekin alfa inbakicept), may help restore immune function and improve survival outcomes in…

AstraZeneca’s LATIFY Trial Misses Primary Endpoint in Previously Treated Advanced NSCLC

Post author:Austin Newman
Post published:January 20, 2026
Post category:non-small cell lung cancer

As reported on PharmaBiz, AstraZeneca’s phase III LATIFY trial has fallen short of its primary objective, with the combination of the ATR inhibitor ceralasertib and the PD‑L1 inhibitor Imfinzi (durvalumab)…

source: shutterstock.com

Adagrasib Shows Promise in Treating KRAS G12C-Mutated NSCLC

Post author:Jessica Lynn
Post published:October 24, 2023
Post category:non-small cell lung cancer

The 2023 World Conference on Lung Cancer took place from September 9-12 this year. During the conference, stakeholders came together to discuss novel research, emerging trends, and other needs…

source: shutterstock.com